×
About 1,000 results

ALLMedicine™ Lymphoblastic Lymphoma Center

Research & Reviews  340 results

T cell lymphoblastic lymphoma with uncommon CD20 expression.
https://doi.org/10.1111/ijlh.13769
International Journal of Laboratory Hematology; Diez-Feijóo R, Rodríguez-Sevilla JJ et. al.

Nov 26th, 2021 - We report an interesting case of a T lymphoblastic lymphoma (T-LBL) with uncommon CD20 expression. Immunophenotype analysis showed TdT expression with positivity of CD3 and CD7 among other T-lineage markers. Other non-T markers such as CD79a or my...

Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Pat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606727
Technology in Cancer Research & Treatment; Dai N, Liu H et. al.

Nov 23rd, 2021 - Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after allogeneic stem cell transplantation (allo-SCT) in ly...

Eruptive nevi in a patient with constitutional mismatch repair deficiency (CMMRD).
https://doi.org/10.1111/pde.14861
Pediatric Dermatology; Vassantachart JM, Zacher NC et. al.

Nov 18th, 2021 - Biallelic mutations in the DNA mismatch repair genes MLH1, MSH2, MSH6, or PMS2 result in one of the most aggressive genetic cancer conditions, constitutional mismatch repair syndrome (CMMRD). We present a case of a 10-year-old boy with biallelic M...

A video-assisted thoracoscopic biopsy for T-cell lymphoblastic lymphoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587505
BMJ Case Reports; Sugimoto H, Kawaguchi K et. al.

Nov 13th, 2021 - A video-assisted thoracoscopic biopsy for T-cell lymphoblastic lymphoma.|2021|Sugimoto H,Kawaguchi K,Hisano M,Nakata K,|

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refr...
https://clinicaltrials.gov/ct2/show/NCT03384654

Nov 5th, 2021 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  26 results

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refr...
https://clinicaltrials.gov/ct2/show/NCT03384654

Nov 5th, 2021 - Screening for eligible participants will be performed within 21 days before administration of the study drug. Participants with B-cell ALL/LL will receive treatment until disease progression, unacceptable toxicity or achievement of CR followed by ...

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

Nov 4th, 2021 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patie...

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03571997

Oct 21st, 2021 - Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of t...

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03181126

Oct 14th, 2021 - This dose-escalating study is to determine the safety, pharmacokinetics, and preliminary efficacy of venetoclax in combination with navitoclax and chemotherapy in adult and pediatric participants with relapsed/refractory acute lymphoblastic leukem...

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00408005

Sep 24th, 2021 - PRIMARY OBJECTIVES: I. To determine, through randomization, the relative safety and efficacy of the addition of nelarabine (Compound 506U78) to augmented Berlin-Frankfurt-Münster (BFM) therapy (Regimen C, Children's Cancer Group [CCG]-1961). II. T...

see more →

News  31 results

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient populati...

FDA Approves New Asparaginase Product for Leukemia
https://www.medscape.com/viewarticle/954149

Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...

Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers
https://www.onclive.com/view/lisaftoclax-shows-early-safety-efficacy-in-relapsed-refractory-cll-sll-and-other-hematologic-cancers

Jun 7th, 2021 - The novel BCL-2 inhibitor lisaftoclax (APG-2575) elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and other hematologic cancers, according to data ...

Venetoclax Shows Activity Against T-ALL in Children
https://www.medscape.com/viewarticle/952355

Jun 3rd, 2021 - Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL) in children and young adults. Among seven patients with T-ALL treated with...

Venetoclax shows activity against T-ALL in children
https://www.mdedge.com/hematology-oncology/article/240841/all/venetoclax-shows-activity-against-t-all-children
Neil Osterweil

Jun 1st, 2021 - Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL) in children and young adults. Among seven patients with T-ALL treated with.

see more →